IN VIVO PROTON MRS DETECTION OF MALIGNANT BREAST CANCER

长期目标是在体内研究和开发质子 磁共振波谱(MRS)在肿瘤早期诊断和治疗中的应用 乳腺癌。短期目标是开发一种光谱成像技术 方法SEL-MQC(选择性多量子相干转移)允许 代谢产物和不饱和脂肪酸的非侵入性质子检测 具有临床可接受的时间效率和空间分辨率的乳腺组织。 来自脂肪和水的强烈信号的强有力的抑制将是 一次扫描即可实现。代谢物和脂质分子将是 随后研究作为分子标记来区分良性和非良性 恶性的人类乳腺肿瘤。我们在这个授权期内的目标是：(1) 在低场2.1T人体MRI/MRS上开发和实现SEL-MQC方法 分光计。无论是低强度的商用磁场梯度还是强的 专门建造的局部磁场梯度将用于 高效的相干选择和过滤。将为以下方面制定协议 乳癌组织中乳酸、胆碱和不饱和脂肪分子的检测 病人。(2)实现了Sel-MQC序列的多切片模块 提高新陈代谢监测空间分辨率的HAdmard矩阵方法 人类乳腺癌的变化。 该项目将把活体质子磁共振波谱扩展到目前的检查范围之外。 大脑中的代谢物。检测肿瘤特异性分子和 乳腺良恶性病变在侵袭前期的鉴别 (可能在任何形态变化之前)质子磁共振波谱将改善 乳腺癌治疗的有效性与乳腺癌的成本-效果 关心。所提出的方法将在其他器官中得到更广泛的应用。

The long-term goal is to investigate and develop in vivo proton magnetic resonance spectroscopy (MRS) for early diagnosis and management of breast cancer. The short-term objective is to develop a spectroscopic imaging method Sel-MQC (Selective Multiple-Quantum Coherence transfer) that permits non-invasive proton detection of metabolites and unsaturated fatty acids in breast tissue with clinical acceptable time efficiency and spatial resolution. Robust suppression of the intensive signals from lipid and water will be achieved in a single scan. The metabolite and lipid molecules will be subsequently investigated as molecular markers to differentiate benign and malignant human breast tumors. Our aims in this grant period are: (1) To develop and implement the Sel-MQC methods on a low field 2.1T human MRI/MRS spectrometer. Both low-strength commercial magnetic field gradients or strong specifically built local magnetic field gradients will be employed for efficient coherence selection and filtering. Protocols will be established for detection of lactate, choline, and unsaturated lipid molecules in breast cancer patients. (2) To develop multi-slice modules of the Sel-MQC sequences using Hadmard matrix approach to improve spatial resolution in monitoring metabolic changes in human breast cancer. The project will extend in vivo proton MRS beyond current limit of examining metabolites inside brain. Detection of tumor-specific molecules and differentiation of malignant and benign breast lesions in pre-invasive stage (possibly before any morphological changes) by proton MRS will improve the efficiency of breast cancer therapy and the cost-effectiveness of breast cancer care. The proposed method will have wider applications in other organs.